Journey Medical (DERM) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update Scottsdale, AZ – Au ...